South Carolina is currently home to 1231 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Premier Neurology, Greenville, South Carolina
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT06094296
Recruiting
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: The Medical University of South Carolina, Charleston, South Carolina
Conditions: NSCLC
Register for Updates
Post-Market Registry of the Patient Experience When Using UltraGuideCTR for Carpal Tunnel Release
NCT06071468
Recruiting
Multicenter prospective registry of patients with symptomatic Carpal Tunnel Syndrome treated with Ultrasound Guided Carpal Tunnel Release (CTR-US).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Ortho SC, Conway, South Carolina
Conditions: Carpal Tunnel Syndrome, CTS
Register for Updates
A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
NCT05645107
Recruiting
The primary purpose of the study is to evaluate whether weekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in participants with hypogammaglobulinemia (HGG) associated with B-cell chronic lymphocytic leukemia (CLL) in comparison to the Placebo plus SMT group.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: GC2202 Study Site 110, Rockville, South Carolina
Conditions: Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia
Register for Updates
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
05/20/2024
Locations: Bogan Sleep Consultants, LLC, Columbia, South Carolina
Conditions: Sleep Apnea, Obstructive
Register for Updates
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05499130
Recruiting
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: To evaluate the efficacy and dose response of the 2 different dose regimens as assessed by multiple standard measures To evaluate the safety and tolerability of the 2 different dose regimens To evaluate the immunogenici... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2024
Locations: Teva Investigational Site 15557, Greenville, South Carolina
Conditions: Crohn Disease, Colitis, Ulcerative
Register for Updates
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants
NCT05412030
Recruiting
This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different dose levels of AFX3772 compared with PCV13. Infants approximately 2 months of age will be enrolled and receive 4 doses of study vaccine over 8 protocol-defined visits spanning a duration of approximately 18 to 21 months. Part 1 is the dose escalation, lead-in portion of t... Read More
Gender:
All
Ages:
Between 42 days and 90 days
Trial Updated:
05/20/2024
Locations: GSK Investigational Site, Greenville, South Carolina
Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal, Pneumonia, Bacterial
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Type2Diabetes, ASCVD
Register for Updates
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847
Recruiting
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have six groups or "parts." Part A will find out how much SEA-CD70 should be given to patients. Part B will use the dose found in Part A... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
NCT03656536
Recruiting
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Greenville Hospital System University Medical Center Institute For Translational Oncology Research, Greenville, South Carolina
Conditions: Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
All
Ages:
All
Trial Updated:
05/20/2024
Locations: Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina
Conditions: Neoplasms
Register for Updates
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Register for Updates